“Hydroxychloroquine did not substantially reduce symptom severity or prevalence over time in non-hospitalized persons with early COVID-19,” the researchers wrote in an article to be published in the Annals of Internal Medicine journal on Thursday.The randomized, placebo-controlled study was conducted on 491 non-hospitalized patients. Owing to test shortages in the United States, only 58% of participants were tested for the disease.Although it was not an endpoint of the study, five individuals who were given hydroxychloroquine were hospitalized or died because of COVID-19, compared with eight people given a placebo.The study “provides strong evidence that hydroxychloroquine offers no benefit in patients with mild illness,” Dr. Neil Schluger of New York Medical College said in an commentary on the study, also scheduled to be published on Thursday.Vocal support from Trump raised expectations for the decades-old drug. In March, Trump said hydroxychloroquine used in combination with the antibiotic azithromycin had “a real chance to be one of the biggest game changers in the history of medicine” with little evidence to back up that claim. He later said he took the drugs preventively after two people who worked at the White House were diagnosed with COVID-19.But several placebo-controlled studies suggest the drug is ineffective to either treat or prevent the disease.”There’s just more and more data accumulated that hydroxychloroquine, at least alone does not really have any effect,” said Dr. David Boulware, the senior investigator of the trial at the University of Minnesota. “Most sort of sensible people have started to move on and really look at other therapies.”Topics : The anti-malaria drug touted by US President Donald Trump as a COVID-19 treatment was ineffective for patients with a mild version of the disease in a study conducted by researchers at the University of Minnesota.About 24% of the patients given hydroxychloroquine in the study had persisting symptoms over a 14-day period, while roughly 30% of the group given a placebo were determined to have persistent symptoms over the same period.The difference was not statistically significant, the researchers said.
The governance of London-listed JPJ Group Plc has this morning confirmed that it has reached a ‘conditional arrangement’ to acquire operating partner Gamesys Limited outright.JPJ has put forward a £490 million transaction, moving to acquire Gamesys platforms and the operated brands of Virgin Games, Virgin Casino, Monopoly Casino, and Heart Bingo.Founded in 2001, Gamesys is the former operating company of JackpotJoy brands, a division sold to former Canadian igaming group Intertain for £430 million in 2015.Following a wholesale corporate reorganisation in 2017, which would see Intertain migrate its listings and holdings onto the London Stock Exchange, a new executive formed JackpotJoy Plc – later renamed as JPJ Group.In its filing, JPJ informs that it will pay £250 million in cash for Gamesys assets (excluding sports betting properties), with a further £175 million contribution added to an enlarged and renamed ‘Gamesys Group Plc’ debt facilities.The transaction represents an estimated multiple of 7.3x adjusted EBITDA for Gamesys assets for the 12 months ending December 2018.Lee Fenton – GamesysShould the acquisition be finalised, a new leadership team will be formed from JPJ and Gamesys executives, with current Gamesys CEO Lee Fenton appointed as Gamesys Group Chief Executive.“I am very excited to join the Enlarged Group as CEO,” said Fenton. “This is a strategically important transaction that adds scale and combines complementary capabilities as the competitive and regulatory environment continues to evolve. The Enlarged Group’s combined brand portfolio, strategically aligned operating structure, technology capabilities and exceptional combined talent base will create significant opportunities for growth in the market.”Fenton will be supported by Robeson Reeves as Group COO and Keith Laslop as Group CFO. Current JPJ Chief Executive Simon Wykes will assume the role of ‘Transition Director’ for a 12-month period following the transaction.Neil Goulden – JPJ GroupAt a governance level, an enlarged Gamesys Group will be led by Neil Goulden as Executive Chairman.“This Acquisition marks an important transformational step in JPJ’s growth, providing significant benefits for shareholders, employees and customers,” said Goulden. “For shareholders, we expect the acquisition to deliver earnings accretion in the first full financial year of ownership, while our employees will benefit from the combination of two companies with a strong commitment to responsible gaming and where the greater scale will further enhance our product development and technology capabilities.“The rationale for the acquisition of Gamesys is based on growth and both teams – at JPJ and our new colleagues joining us from Gamesys – are excited and motivated by the great opportunity which lies ahead.” Share Submit Gamesys halts UK advertising during lockdown April 23, 2020 Related Articles StumbleUpon Enlarged Gamesys returns to UK growth eyeing FTSE250 spot March 17, 2020 Gamesys maintains UK growth as Euro regulatory headwinds stall performance August 11, 2020 Share